TAK-531 / Takeda, JCR Pharma - LARVOL DELTA

Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome (clinicaltrials.gov) - P1; N=6; Completed; Sponsor: ArmaGen, Inc; Recruiting ➔ Completed; Trial completion date: Oct 2017 ➔ Mar 2017; Trial primary completion date: Jul 2017 ➔ Mar 2017

Trial completion • Trial completion date • Trial primary completion date • Biosimilar • Gene Therapies